Published in JAMA Internal Medicine · View the paper (DOI)
A study investigated whether early tocilizumab treatment reduced the risk of death among critically ill COVID-19 patients. The results showed that patients treated with tocilizumab in the first two days after admission had a lower risk of death compared to those not treated early.
Coverage from 2 institutions